Effect of berberine on COVID-19

Phase 2

Recruiting

• Conditions: Covid-19.; COVID-19 Disease; U07.1

• Registration Number: IRCT20081019001369N2
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Patients with covid-19 symptoms
Indication of home quarantine and outpatient medication

Exclusion Criteria

Patients over 65 years of age
Patients connected to a catheter or under chemotherapy
Patients taking cytotoxic drugs or corticosteroids
Child patients
Pregnant and lactating patients
Diabetic patients
Patients with severe renal insufficiency as well as liver failure

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time interval until clinical symptoms improve. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: time of recovery.

Secondary Outcome Measures

Name	Time	Method
Fever. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Thermometer.;Lymphopenia. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: Cell counter device.;CRP. Timepoint: 3 days, 1 week and 2 weeks after treatment. Method of measurement: CRP kit.